ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates

.release-content span.prnews_span{font-size:8pt;font-family:"Arial";color:black}.release-content a.prnews_a{color:blue}.release-content li.prnews_li{font-size:8pt;font-family:"Arial";color:black}.release-content p.prnews_p{font-size:0.62em;font-family:"Arial";color:black;margin:0in}.release-content .prngen17{padding-right:0.83em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen21{padding-right:0.50em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen22{padding-right:0.83em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen10{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen3{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen18{padding-right:0.83em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen2{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen19{padding-right:0.83em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen11{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen20{padding-right:0.50em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen13{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen5{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen15{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 3PT double;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen4{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen26{padding-right:0.83em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 3PT double;border-left:black 1pt}.release-content .prngen6{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen8{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 1pt;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen14{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 3PT double;border-left:black 1pt}.release-content .prngen9{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen25{padding-right:0.50em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 3PT double;border-left:black 1pt}.release-content .prngen28{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:CENTER;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen12{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 0.5pt solid;border-left:black 1pt}.release-content .prngen16{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;text-align:RIGHT;border-top:black 0.5pt solid;border-right:black 1pt;border-bottom:black 3PT double;border-left:black 1pt}.release-content .prngen27{padding-right:0.33em;padding-left:0.17em;vertical-align:BOTTOM;font-size:8PT;font-family:ARIAL;color:BLACK;margin:0em;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen30{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;border-top:black 0pt;border-right:black 0pt;border-bottom:black 0pt;border-left:black 0pt}.release-content .prngen7{padding-right:0.17em;padding-left:0.17em;vertical-align:BOTTOM;border-top:black 1pt;border-right:black 1pt;border-bottom:black 1pt;border-left:black 1pt}.release-content .prngen29{padding-right:0.17em;padding-left:0.17em;vertical-align:TOP;border-top:black 0pt;border-right:black 0pt;border-bottom:black 0pt;border-left:black 0pt}.release-content .prngen32{text-align:CENTER;margin-top:0em;margin-right:0em;margin-bottom:0em;margin-left:0.33em !important}.release-content .prnrbrb1{border-right:black 1pt}.release-content .prnsblb1{border-left:black 1pt}.release-content .prnml4{margin-top:0em;margin-right:0em;margin-bottom:0em;margin-left:0.33em !important}.release-content .prnpl2{padding-left:0.17em}.release-content .prnml8{margin-top:0em;margin-right:0em;margin-bottom:0em;margin-left:0.67em !important}.release-content .prntac{text-align:CENTER}.release-content .prnbbbs{border-bottom:black 0.5pt solid}.release-content .prntar{text-align:RIGHT}.release-content .prnsbtb1{border-top:black 1pt}.release-content .prnpr2{padding-right:0.17em}.release-content .prnbcc{border-collapse:COLLAPSE}.release-content .prnpr6{padding-right:0.50em}.release-content .prnvab{vertical-align:BOTTOM}

ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates

Inne wiadomości firmowe